GlassScriptPhysician profile
Hamid Borghei Razavi
NPI 1326573478
$5,573.61
in general payments reported to CMS, 2019-2025
20 companies · $1,875 in 2025
The $1,875 reported for 2025 was more than what a typical Neurological Surgery provider received nationally (typical 2025 total: $604).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,929 · 2021: $107 · 2022: $435 · 2023: $504 · 2024: $724 · 2025: $1,875.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,893 · Consulting Fee: $1,210.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,892.58 |
| Consulting Fee | $1,210.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Monteris Medical Corporation | $1,775.59 | 2019-2025 | Neuroblate |
| Medical Device Business Services, INC. | $1,210.00 | 2025 | |
| Depuy Synthes Sales INC. | $766.60 | 2021-2025 | Na |
| Stryker Corporation | $588.95 | 2019-2025 | Adherus Autospray Dural Sealant, Core |
| Integra Lifesciences Corporation | $203.46 | 2019-2021 | |
| Acclarent, INC | $147.14 | 2022 | |
| Gt Medical Technologies, INC | $146.35 | 2025 | Gammatile |
| Baxter Healthcare | $144.00 | 2019 | |
| Karl Storz Endoscopy-America | $142.43 | 2019 | |
| Medtronic, INC. | $126.04 | 2024 | Stealthstation S8 Platform |
| Emd Serono, INC. | $72.53 | 2022-2023 | Mavenclad |
| Ucb, INC. | $40.16 | 2025 | Fintepla |
| Microtransponder, INC. | $36.88 | 2024 | |
| Teva Pharmaceuticals USA, INC. | $35.43 | 2024 | Austedo Xr |
| Neurelis, INC. | $32.74 | 2023-2025 | Valtoco |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mallinckrodt Hospital Products INC. | $29.76 | 2025 | Acthar |
| Omniscient Neurotechnology America LTD | $25.05 | 2023 | Quicktome |
| Genentech USA, INC. | $18.58 | 2022 | |
| Neurocrine Biosciences, INC. | $17.15 | 2024 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $14.77 | 2025 | Ultomiris |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hamid Borghei Razavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.